A Medical Device Daily

Generex Biotechnology (Worcester, Massachusetts) a developer in drug delivery for metabolic diseases through the inner lining of the mouth, reported that it has received five new patents in Canada, Australia, New Zealand, Brazil and Lebanon.

The patents provide additional protection for Generex's proprietary compositions and methodologies for delivering pharmaceuticals in buccal applications. With the addition of these patents, Generex now holds an aggregate of 146 patents worldwide, including 21 in the U.S., and has an aggregate of 116 patent applications pending in various jurisdictions throughout the world.

President/CEO Anna Gluskin said, "Generex continues to bolster its intellectual property as we begin to commercialize our revolutionary drug delivery systems throughout the world. We have invested significant resources in developing and protecting our processes and these patents represent another step forward as we continue toward building a solid foundation for the future of our company."